Health Care • Biotechnology: Pharmaceutical Preparations
$2.33 ▼ -0.07
(-2.92%)
MKT CAP: $152.9M • VOL: 766.1K
52W L $1 52W H $5
ROARABLE / RQD
E • 24/100
PIOTROSKI
2 / 9
MGNX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $149.5M | $150.0M | $58.7M |
| YoY Revenue Growth % | -0.3% | +155.3% | — |
| Gross Profit | $149.5M | $149.1M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$72.8M | -$110.6M | -$168.2M |
| Operating Margin % | -48.7% | -73.7% | -80.0% |
| Net Income (GAAP) | -$74.6K | -$67.0K | -$9.1K |
| EBITDA (Normalized) | -$71.3M | -$107.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$81.0M | -$68.4M | -$78.2M |
| Capital Expenditures (CapEx) | $1.9M | $3.7M | — |
| Free Cash Flow (FCF) | -$83.0M | -$72.1M | -$78.2M |
| FCF Margin % | -55.5% | -48.1% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $57.2M | $182.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $55.6M | $116.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MGNX.